Loading
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Previous close
$6.20
+$0.05 · +0.81%
Regular session · ET · Market data may be delayed.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Day range
Current $6.20
52-week range
Current $6.20
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
11
Overpriced
Sentiment
73
Bullish
Risk
54
Elevated Risk
Momentum
76
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Day range
Current $6.20
52-week range
Current $6.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1M USD | 5.72M USD | 1.66M USD | 652K USD | 30.02M USD |
| Cost of goods sold | 2.95M USD | 4.89M USD | 4.04M USD | 82.2M USD | 1.38M USD |
| Gross profit | −1.95M USD | 827K USD | −2.39M USD | −81.55M USD | 28.64M USD |
| Research and development | 35.27M USD | 67.21M USD | 74.31M USD | 82.9M USD | 56.56M USD |
| Selling, general, and administrative | 17.24M USD | 19.08M USD | 19.3M USD | 19.68M USD | 18.72M USD |
| Operating expenses | 49.56M USD | 81.39M USD | 89.57M USD | 21.78M USD | 73.91M USD |
| Interest income | 2.7M USD | 5.17M USD | 4.67M USD | 1.59M USD | 625K USD |
| Depreciation and amortization | 3.69M USD | 3.83M USD | 4.04M USD | 3.07M USD | 1.38M USD |
| Operating income | −51.51M USD | −80.57M USD | −91.96M USD | −103.33M USD | −45.27M USD |
| Net income | −48.81M USD | −75.41M USD | −87.3M USD | −101.95M USD | −44.97M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$13.20
112.90% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI16.73M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM9.95M0.01%77.55B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF5.44M0.01%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO3.18M0.02%14.32B USD0.24%$367.63+0.54%
Vanguard Russell 2000 ETFVTWO2.43M0.01%17.4B USD0.06%$116.76+0.36%
Fidelity Enhanced Small Cap ETFFESM2.31M0.04%6.49B USD0.28%$46.36+0.78%
iShares Micro-Cap ETFIWC1.32M0.09%1.44B USD0.60%$190.84+0.39%
Vanguard Health Care ETFVHT1.09M0.01%20.9B USD0.09%$310.74-0.17%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
